| Literature DB >> 32209060 |
Dévi Rita Rochemont1, Emmanuelle Mimeau2, Caroline Misslin-Tritsch3, Martine Papaix-Puech4, Emmanuel Delmas5,6, Yannick Bejot7, Bertrand DeToffol8, Isabelle Fournel5,6, Mathieu Nacher9,10.
Abstract
BACKGROUND: French Guiana has the highest incidence of ischemic and hemorrhagic stroke of all French territories. However, there is no further information on the epidemiology and management of stroke in French Guiana. Our goal was to describe the characteristics of patients in French Guiana in order to generate hypotheses regarding the determinants explaining the magnitude of this public health problem.Entities:
Keywords: Emergency care; Epidemiology; France; French Guiana; Stroke
Year: 2020 PMID: 32209060 PMCID: PMC7093981 DOI: 10.1186/s12883-020-01650-2
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.474
Fig. 1Sociodemographic characteristics of strokes in French Guiana
Socio-demographic and baseline characteristics according to stroke mechanism in French Guiana. India study-French Guiana
| Characteristics | All patients | Ischemic stroke | Intracerebral hemorrhage |
|---|---|---|---|
| Age | |||
| < 50 | 60 (20.1) | 43 (18.3) | 17 (26.5) |
| 50–65 | 106 (35.5) | 86 (36.7) | 20 (31.2) |
| 65–80 | 96 (32.2) | 77 (32.9) | 19 (29.6) |
| ≥80 | 36 (12) | 28 (11.9) | 8 (12.5) |
| Male gender | 190 (63.7) | 146 (62.3) | 44 (68.7) |
| BMI± | |||
| < 20 | 16 (5.3) | 11 (4.7) | 5 (7.8) |
| 20–25 | 82 (27.5) | 60 (25.6) | 22 (34.3) |
| 25–30 | 82 (27.5) | 68 (29) | 14 (21.8) |
| > = 30 | 52 (17.4) | 41 (17.5) | 11 (17.1) |
| Unknown | 66 (22.1) | 54 (23) | 12 (18.7) |
| Hypertension± | 208 (70.2) | 164 (70.3) | 44 (69.8) |
| Diabetes± | 74 (24.9) | 67 (28.7) | 7 (10.9) |
| Hypercholesterolemia± | 50 (17) | 42 (18.1) | 8 (12.7) |
| Chronic heart failure± | 16 (5.4) | 12 (5.1) | 4 (6.2) |
| Alcohol ≥ 2 drinks/day± | 52 (17.9) | 35 (15.2) | 17 (27.8) |
| Tobacco status± | |||
| Current smoker | 64 (21.6) | 53 (22.7) | 11 (17.7) |
| Previous smoker | 48 (16.2) | 37 (15.8) | 11 (17.7) |
| Non smoker | 183 (62) | 143 (61.3) | 40 (64.5) |
| Atrial fibrillation± | 19 (6.5) | 17 (7.4) | 2 (3.1) |
| Prior medical history | |||
| Prior transient ischemic attack | 33 (11) | 33 (14.1) | 0 |
| Prior myocardial infarction | 8 (2.6) | 5 (2.1) | 3 (4.6) |
| Prior angina pectoris | 9 (3) | 6 (2.5) | 3 (4.6) |
| Prior history of lower limb arteriopathy | 13 (4.3) | 13 (5.5) | 0 |
| Prior history of vascular surgery | 7 (2.3) | 7 (2.9) | 0 |
| Prior history of angioplasty | 7 (2.3) | 6 (2.5) | 1 (1.5) |
| Pre-morbid treatment | |||
| Antiplatelet therapy | 41 (13.7) | 34 (14.5) | 7 (10.9) |
| Anticoagulant therapy± | 19 (6.4) | 10 (4.3) | 9 (14) |
| Antihypertensive drug± | 153 (51.6) | 120 (51.7) | 33 (51.5) |
| Statin± | 38 (12.7) | 31 (13.3) | 7 (10.9) |
| Oral antidiabetic drug± | 48 (16.2) | 44 (18.9) | 4 (6.2) |
| Psychotropic drug± | 15 (5) | 9 (3.8) | 6 (9.3) |
| Insulin± | 24 (8) | 21 (9) | 3 (4.6) |
| Oral contraception ±(woman only) | 7 (6.4) | 7 (7.9) | 0 |
| Substitution hormonotherapy ±(woman only) | 2 (1.9) | 0 | 2 (1.9) |
| Ischaemic stroke classification ( | |||
| Lacunar | 57 (24.3) | ||
| Large-artery | 38 (16.2) | ||
| Cardioembolism | 28 (11.9) | ||
| Other | 111 (47.4) | ||
| Admission NIHSS score± | |||
| 0–3 | 89 (31.4) | 75 (33.7) | 14 (22.9) |
| 4–9 | 97 (34.2) | 84 (37.8) | 13 (21.3) |
| ≥10 | 97 (34.2) | 63 (28.3) | 34 (55.7) |
| mRS at discharge± | |||
| 0 | 40 (14.3) | 37 (17.1) | 3 (4.8) |
| 1–2 | 102 (36.6) | 88 (40.7) | 14 (22.5) |
| 3–4 | 96 (34.5) | 67 (31) | 29 (46.7) |
± missing values: BMI = 66; HTA = 2; Diabetes = 1; Hypercholesterolemia = 4; Chronic heart failure = 3; Alcohol = 8;Tobbaco = 3; AF = 6; anticoagulant = 2; antihypertensive = 2; statin = 1; oral antidiabetic = 2; psychotropic = 1; insulin = 1; oral contraception = 2; Sub hormonotherapy = 4; pre stroke mRS = 1; NIHSS at admission = 15; Barthel score = 2
Patterns of management according to stroke mechanism. INDIA study-French Guiana
| Characteristics | All patients | Ischemic stroke | Intra-cerebral hemorrhage |
|---|---|---|---|
| Thrombolysis* | 32 (10.7) | 32 (13.6) | 0 |
| During in-hospital stay | |||
| Medical treatment | |||
| Antiplatelet therapy ± * | 181 (60.9) | 181 (77.6) | 0 |
| Antihypertensive drug ± | 76 (25.8) | 61 (26.5) | 15 (23.4) |
| Heparin ± | 129 (43.8) | 122 (53) | 7 (10.9) |
| Injectable nicardipine ± | 98 (33.2) | 55 (23.8) | 43 (67.1) |
| Insulin ± | 42 (14.1) | 38 (16.3) | 4 (6.20) |
| Oral anti diabetics ± | 16 (5.4) | 16 (6.9) | 0 |
| Urinary catheter | 35 (11.7) | 19 (8.1) | 16 (25) |
| Other examinations | |||
| CT scanner | 253 (84.9) | 193 (82.4) | 60 (93.7) |
| MRI | 179 (6) | 152 (64.9) | 27 (42.1) |
| Ultrasonography of the supra-aortic arteries | 145 (48.6) | 138 (58.9) | 7 (10.9) |
| Angio-scanner | 169 (56.7) | 139 (59.4) | 30 (46.8) |
| ECG± | 294 (98.9) | 233 (99.5) | 61 (96.8) |
| Holter± | 113 (38.1) | 110 (47.2) | 3 (4.7) |
| Trans-oesophageal ultrasonography | 17 (5.7) | 17 (7.2) | 0 |
| Trans-thoracic echocardiography± | 225 (75.7) | 190 (81.2) | 35 (55.5) |
| MRI as first radiological examination | 110 (36.9) | 92 (39.3) | 18 (28.1) |
| Had both MRI and scanner | 135 (45.3) | 112 (47.9) | 23 (35.9) |
| After discharge | |||
| Medical treatment | |||
| Antiplatelet therapy± | 197 (72.1) | 196 (87.8) | 1 (2) |
| Anticoagulant therapy± | 62 (22.7) | 51 (22.8) | 11 (22) |
| Antihypertensive drug± | 226 (82.7) | 182 (81.6) | 44 (88) |
| Statin± | 187 (68.5) | 180 (80.7) | 7 (14) |
| Non-medical treatment | |||
| Speech therapy± | 42 (15.9) | 33 (12.5) | 9 (18.7) |
| Physical therapy± | 136 (51.5) | 106 (49.3) | 30 (61.2) |
| Care pathways– admitted in … | |||
| UNV | 1 | ||
| Neurology± | 181 (61.3) | 144 (62) | 37 (58.7) |
| Short stay unit (UHCD)± | 177 (60) | 135 (45.7) | 42 (66.6) |
| ICU± | 11 (3.7) | 2 (0.86) | 9 (14.2) |
| Medecine± | 65 (22) | 53 (22.8) | 12 (19) |
| Otherunits± | 43 (14.5) | 37 (15.9) | 6 (9.5) |
| Follow up checkup programmed ± | 188 (73.4) | 152 (73) | 36 (75) |
| Follow up checkup done at hospital | 139 (50.3) | 109 (48.6) | 30 (57.6) |
| Follow up checkup done: Examinations done after discharge | |||
| MIR | 33 (23.70) | 19 (17.40) | 14 (46.60) |
| Arteriography | 3 (2.10) | 2 (1.80) | 1 (0.72) |
| Trans-esophagealultrasonography | 10 (7.10) | 10 (9.10) | 0 |
| Transthoracicultrasonography | 4 (2.80) | 4 (3.60) | 0 |
| Holter± | 12 (8.70) | 11 (10.10) | 1 (3.30) |
± Missing values:
∙ During care: Antiplatelet therapy = 1; Antihypertensive drug = 4; Heparin = 4; Injectable nicardipine = 3; Insulin = 1; Oral anti diabetics = 2; ECG = 1; Holter = 2; Trans-thoracic echocardiography = 1
∙ At discharge: Antiplatelet therapy = 25; Anticoagulant therapy = 25; Antihypertensive drug = 25; Statin = 25; Speech therapy = 34; Physical therapy = 34
∙ Care pathway: Neurology = 3; Short Stay Unit = 3; ICU = 3; Medicine = 3; other = 3; Follow up check-up programmed = 42; Follow up check-up done = 22
∙ Follow up checkupdone: Holter = 1
*significant p value